Treatment of bone disorders
CA 2020752 C · Owner: Amylin Pharmaceuticals, Inc. · Inventors: Macintyre, Iain
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Use of amylin, or variants of amylin, as well as amylin agonists, for the treatment of bone disorders in particular, osteoporosis, Paget's disease and malignant deposits in bone, bone loss of malignancy or endocrine disorders or autoimmune arthritides or immobility and disuse, and in other conditions where a hypocalcaemic effect is of benefit. Functional peptide fragments of amylin, or a variant of amylin or amylin fragment are provided as well as a soluble amylin amylin fragments, or, variants thereof or a lyophilized product, or an oral, formulation for use alone or in combination with other agents, including insulin (or insulin-stimulating agents including but, not limited to the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 9, 1990 and granted December 24, 1996. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 9, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 9, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.